A citation-based method for searching scientific literature

Peter A Campochiaro. Prog Retin Eye Res 2015
Times Cited: 223







List of co-cited articles
707 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis.
Kip M Connor, Nathan M Krah, Roberta J Dennison, Christopher M Aderman, Jing Chen, Karen I Guerin, Przemyslaw Sapieha, Andreas Stahl, Keirnan L Willett, Lois E H Smith. Nat Protoc 2009
419
14

Ocular neovascularization.
Peter A Campochiaro. J Mol Med (Berl) 2013
224
13

Oxygen-induced retinopathy in the mouse.
L E Smith, E Wesolowski, A McLellan, S K Kostyk, R D'Amato, R Sullivan, P A D'Amore. Invest Ophthalmol Vis Sci 1994
12

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wan Ling Wong, Xinyi Su, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-Yu Cheng, Tien Yin Wong. Lancet Glob Health 2014
11

Vascular endothelial growth factor in eye disease.
J S Penn, A Madan, R B Caldwell, M Bartoli, R W Caldwell, M E Hartnett. Prog Retin Eye Res 2008
422
11

Ranibizumab for neovascular age-related macular degeneration.
Philip J Rosenfeld, David M Brown, Jeffrey S Heier, David S Boyer, Peter K Kaiser, Carol Y Chung, Robert Y Kim. N Engl J Med 2006
10

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Jörg T Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A Barathi, Chui Ming Gemmy Cheung, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken,[...]. EMBO Mol Med 2016
88
10

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Pravin U Dugel, Adrian Koh, Yuichiro Ogura, Glenn J Jaffe, Ursula Schmidt-Erfurth, David M Brown, Andre V Gomes, James Warburton, Andreas Weichselberger, Frank G Holz. Ophthalmology 2020
208
9

Ten years of anti-vascular endothelial growth factor therapy.
Napoleone Ferrara, Anthony P Adamis. Nat Rev Drug Discov 2016
426
9

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
L P Aiello, R L Avery, P G Arrigg, B A Keyt, H D Jampel, S T Shah, L R Pasquale, H Thieme, M A Iwamoto, J E Park. N Engl J Med 1994
9

Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice.
Vincent Lambert, Julie Lecomte, Sylvain Hansen, Silvia Blacher, Maria-Luz Alvarez Gonzalez, Ingrid Struman, Nor Eddine Sounni, Eric Rozet, Pascal de Tullio, Jean Michel Foidart,[...]. Nat Protoc 2013
183
9

Diabetic retinopathy.
David A Antonetti, Ronald Klein, Thomas W Gardner. N Engl J Med 2012
937
9

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Jayashree Sahni, Sunil S Patel, Pravin U Dugel, Arshad M Khanani, Chirag D Jhaveri, Charles C Wykoff, Vrinda S Hershberger, Meike Pauly-Evers, Shamil Sadikhov, Piotr Szczesny,[...]. Ophthalmology 2019
68
11

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F Martin, Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe. N Engl J Med 2011
8


Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S Heier, David M Brown, Victor Chong, Jean-Francois Korobelnik, Peter K Kaiser, Quan Dong Nguyen, Bernd Kirchhof, Allen Ho, Yuichiro Ogura, George D Yancopoulos,[...]. Ophthalmology 2012
8

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
John A Wells, Adam R Glassman, Allison R Ayala, Lee M Jampol, Neil M Bressler, Susan B Bressler, Alexander J Brucker, Frederick L Ferris, G Robert Hampton, Chirag Jhaveri,[...]. Ophthalmology 2016
431
8

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
John A Wells, Adam R Glassman, Allison R Ayala, Lee M Jampol, Lloyd Paul Aiello, Andrew N Antoszyk, Bambi Arnold-Bush, Carl W Baker, Neil M Bressler, David J Browning,[...]. N Engl J Med 2015
834
8

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.
Frank G Holz, Ramin Tadayoni, Stephen Beatty, Alan Berger, Matteo G Cereda, Rafael Cortez, Carel B Hoyng, Philip Hykin, Giovanni Staurenghi, Stephanie Heldner,[...]. Br J Ophthalmol 2015
303
7

Global prevalence and major risk factors of diabetic retinopathy.
Joanne W Y Yau, Sophie L Rogers, Ryo Kawasaki, Ecosse L Lamoureux, Jonathan W Kowalski, Toke Bek, Shih-Jen Chen, Jacqueline M Dekker, Astrid Fletcher, Jakob Grauslund,[...]. Diabetes Care 2012
7

Animal models of choroidal and retinal neovascularization.
Hans E Grossniklaus, Shin J Kang, Lennart Berglin. Prog Retin Eye Res 2010
202
7


Role of Inflammation in Diabetic Retinopathy.
Anne Rübsam, Sonia Parikh, Patrice E Fort. Int J Mol Sci 2018
209
7

Angiopoietin-2 is critical for cytokine-induced vascular leakage.
Andrew V Benest, Karoline Kruse, Soniya Savant, Markus Thomas, Anna M Laib, Elias K Loos, Ulrike Fiedler, Hellmut G Augustin. PLoS One 2013
89
6

Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration.
Usha Chakravarthy, Clare Bailey, David Brown, Peter Campochiaro, Mark Chittum, Karl Csaky, Adnan Tufail, Paul Yates, Patrick Cech, Mylene Giraudon,[...]. Ophthalmol Retina 2017
31
19

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Daniel F Martin, Maureen G Maguire, Stuart L Fine, Gui-shuang Ying, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Maryann Redford, Frederick L Ferris. Ophthalmology 2012
6

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
Helen A Mintz-Hittner, Kathleen A Kennedy, Alice Z Chuang. N Engl J Med 2011
749
6

Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression.
H Ozaki, A Y Yu, N Della, K Ozaki, J D Luna, H Yamada, S F Hackett, N Okamoto, D J Zack, G L Semenza,[...]. Invest Ophthalmol Vis Sci 1999
262
6

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
David M Brown, Peter K Kaiser, Mark Michels, Gisele Soubrane, Jeffrey S Heier, Robert Y Kim, Judy P Sy, Susan Schneider. N Engl J Med 2006
6

Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1.
Brian D Kelly, Sean F Hackett, Kiichi Hirota, Yuji Oshima, Zheqing Cai, Shannon Berg-Dixon, Ashley Rowan, Zhijiang Yan, Peter A Campochiaro, Gregg L Semenza. Circ Res 2003
437
6

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.
Hellmut G Augustin, Gou Young Koh, Gavin Thurston, Kari Alitalo. Nat Rev Mol Cell Biol 2009
908
6

Therapeutic targeting of the angiopoietin-TIE pathway.
Pipsa Saharinen, Lauri Eklund, Kari Alitalo. Nat Rev Drug Discov 2017
177
6

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Soraya Rofagha, Robert B Bhisitkul, David S Boyer, SriniVas R Sadda, Kang Zhang. Ophthalmology 2013
611
6

Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.
Jikui Shen, Maike Frye, Bonnie L Lee, Jessica L Reinardy, Joseph M McClung, Kun Ding, Masashi Kojima, Huiming Xia, Christopher Seidel, Raquel Lima e Silva,[...]. J Clin Invest 2014
123
6

Retinal vasculature development in health and disease.
Senthil Selvam, Tejas Kumar, Marcus Fruttiger. Prog Retin Eye Res 2018
90
6

Diabetic retinopathy.
Ning Cheung, Paul Mitchell, Tien Yin Wong. Lancet 2010
6

Retinal microglia: just bystander or target for therapy?
Marcus Karlstetter, Rebecca Scholz, Matt Rutar, Wai T Wong, Jan M Provis, Thomas Langmann. Prog Retin Eye Res 2015
273
6

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Arshad M Khanani, Sunil S Patel, Philip J Ferrone, Aaron Osborne, Jayashree Sahni, Susanna Grzeschik, Karen Basu, Jason S Ehrlich, Zdenka Haskova, Pravin U Dugel. JAMA Ophthalmol 2020
34
17

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Sharon D Solomon, Kristina Lindsley, Satyanarayana S Vedula, Magdalena G Krzystolik, Barbara S Hawkins. Cochrane Database Syst Rev 2019
80
7

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Quan Dong Nguyen, David M Brown, Dennis M Marcus, David S Boyer, Sunil Patel, Leonard Feiner, Andrea Gibson, Judy Sy, Amy Chen Rundle, J Jill Hopkins,[...]. Ophthalmology 2012
969
5

Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.
Ramya Krishna Vadlapatla, Aswani Dutt Vadlapudi, Ashim K Mitra. Curr Drug Targets 2013
74
6

Hypoxia-Inducible Factor-1α Is Associated With Sprouting Angiogenesis in the Murine Laser-Induced Choroidal Neovascularization Model.
Helder André, Selcuk Tunik, Monica Aronsson, Anders Kvanta. Invest Ophthalmol Vis Sci 2015
33
15

Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis.
Seth R Flaxman, Rupert R A Bourne, Serge Resnikoff, Peter Ackland, Tasanee Braithwaite, Maria V Cicinelli, Aditi Das, Jost B Jonas, Jill Keeffe, John H Kempen,[...]. Lancet Glob Health 2017
957
5

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.
Kazuaki Nishijima, Yin-Shan Ng, Lichun Zhong, John Bradley, William Schubert, Nobuo Jo, Jo Akita, Steven J Samuelsson, Gregory S Robinson, Anthony P Adamis,[...]. Am J Pathol 2007
513
5

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Prethy Rao, Flora Lum, Kevin Wood, Craig Salman, Bhavya Burugapalli, Rebecca Hall, Sukhminder Singh, David W Parke, George A Williams. Ophthalmology 2018
65
7


The mouse retina as an angiogenesis model.
Andreas Stahl, Kip M Connor, Przemyslaw Sapieha, Jing Chen, Roberta J Dennison, Nathan M Krah, Molly R Seaward, Keirnan L Willett, Christopher M Aderman, Karen I Guerin,[...]. Invest Ophthalmol Vis Sci 2010
395
5

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
Juan E Grunwald, Ebenezer Daniel, Jiayan Huang, Gui-Shuang Ying, Maureen G Maguire, Cynthia A Toth, Glenn J Jaffe, Stuart L Fine, Barbara Blodi, Michael L Klein,[...]. Ophthalmology 2014
342
5

Oxidative stress and diabetic retinopathy.
Renu A Kowluru, Pooi-See Chan. Exp Diabetes Res 2007
364
5

Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions.
Ingeborg Klaassen, Cornelis J F Van Noorden, Reinier O Schlingemann. Prog Retin Eye Res 2013
352
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.